Ripple kopen? Dit zijn de mogelijkheden

Galapagos Aandeel

111,05EUR -1,05EUR -0,94%

Galapagos - Profiel

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.


Eigenaar in %
Gilead Sciences, Inc.12,41
Van Herk Investments BV9,88
Johnson & Johnson7,61
Gestion Deelnemingen V BV7,40
Wellington Management Co. LLP6,28
Fidelity Management & Research Co.4,66
Schroder Investment Management Ltd.4,25
Capital Research & Management Co. (World Investors)4,08
Delta Lloyd Asset Management NV3,85
Baker Bros. Advisors LP3,85
The Vanguard Group, Inc.2,28
GlaxoSmithKline Plc1,68
Federated Global Investment Management Corp.1,16
T. Rowe Price International Ltd.1,04


Industriepark Mechelen Noord, 2800 Mechelen
Telefoon: 3215342900
Fax: 3215342901


Raj B. Parekh, PhD
Andre Hoekema, PhD
Chief Business Officer
Onno van de Stolpe, PhD
Chief Executive Officer & Executive Director
Walid Abi-Saab, MD
Chief Medical Officer
Bart Filius, MBA
Chief Operating & Financial Officer
Piet Wigerinck, PhD
Chief Scientific Officer
Paul van der Horst
Director-Business Development & IR
Evelyn Fox
Director-Communications & Head-Media Relations
Sofie Van Gijsel
Director-Investor Relations
Peter Guenter
Independent Director
Werner Cautreels PhD, EMBA
Independent Non-Executive Director
Katrine S. Bosley
Independent Non-Executive Director
Harrold van Barlingen, PhD
Independent Non-Executive Director
Howard Mitchell Rowe, PhD
Independent Non-Executive Director
Christine Mummery, PhD
Independent Non-Executive Director
Mary Kerr PhD, MBA
Independent Non-Executive Director
Xavier Marie Bernard Cecile Maes
Carmen Vroonen
Senior Director-Communications & Public Affairs
Elizabeth Goodwin
VP-Corporate Communications & Investor Relations

Invoer toevoegen